SAN DIEGO, Feb. 25 /PRNewswire/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today that the International Federation of Sports Medicine (FIMS) and its Executive Committee has selected Celadrin(R) Topical Cream as its Official Pain Relieving Cream. FIMS's goal since 1928 was to provide the best medical care for the athletes of the summer and winter Olympic Games. Now it has expanded its goal to provide the most advanced knowledge and technologies in sports medicine for world class athletes and exercise enthusiasts.
Commenting on the recommendation, Mr. William Spencer, Imagenetix's Chief Executive Officer said, "We are extremely excited to have our Inflame Away(R)- Celadrin(R) selected by this World Class organization. FIMS consists of national associations of top sports medicine physicians, specialists and researchers and their endorsement is indicative of the strong science surrounding the product and the effective results the product has produced in athletes. The highly compelling scientific data from clinical trials in the area of pain management and reduction of inflammation was key to their recommendation."
Celadrin(R) has been endorsed by FIMS as the official pain relieving cream for a period encompassing the years 2008 until 2012. Celadrin(R) will maintain this exclusive and prestigious association throughout this athletic cycle.
Mr. Spencer added, "We believe this endorsement will be instrumental in our retail launch of our branded product and will be the cornerstone of an advertising program utilizing testimonials of athletes alike that have used and endorse the product."
Dr. Walter Frontera, the president of FIMS, stated that "FIMS is very impressed with the scientifically validated Celadrin(R) Topical Pain Cream. After reviewing the scientific attributes of Celadrin(R) Topical Pain Cream, FIMS is convinced of its efficacy for the treatment of soft tissue injuries that may interfere with sports performance."
The Federation Internationale de Medecine du Sports (FIMS)/International Federation of Sports Medicine is an international organization comprised of individual members, national associations, and multinational groups, with a common involvement with sports medicine on all continents. FIMS aims primarily to promote the study and development of sports medicine throughout the world, to assist athletes in achieving optimal performance, and to enhance health through the practice of exercise and physical activity in the general population. http://www.fims.org.
Based in San Diego, California, Imagenetix, (OTC Bulletin Board: IAGX) is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops, formulates and private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(R)- Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information on Celadrin(R), please visit, http://www.celadrin.com.
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed and will periodically file with the Securities Exchange Commission.
|SOURCE Imagenetix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved